Trending

Mundipharma

New deals extend Mundipharma biosimilar reach

New deals extend Mundipharma biosimilar reach

Mundipharma has fleshed out its range of biosimilars by acquiring Tuznue, a version of Roche’s breast cancer blockbuster

X

New deals extend Mundipharma biosimilar reach

https://pharmaphorum.com/news-market-access/new-deals-extend-mundipharma-biosimilar-reach/

Mundipharma, Grünenthal accused of kickbacks in Italy

Mundipharma, Grünenthal accused of kickbacks in Italy

Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor

X

Mundipharma, Grünenthal accused of kickbacks in Italy

https://pharmaphorum.com/news/mundipharma-grunenthal-italy-opioid/

Mundipharma’s Neulasta biosimilar approved in EU

Mundipharma’s Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU

X

Mundipharma’s Neulasta biosimilar approved in EU

https://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/

Mundipharma appoints former GSK exec as CFO

Mundipharma appoints former GSK exec as CFO

The Mundipharma network of independent pharma companies has appointed Arnaud Breabout as chief financial officer. Breabout was most

X

Mundipharma appoints former GSK exec as CFO

https://pharmaphorum.com/news/mundipharma-appoints-former-gsk-exec-as-cfo/

Mundipharma buys Spanish biosimilars firm Cinfa Biotech

Mundipharma buys Spanish biosimilars firm Cinfa Biotech

Mundipharma, a network of independent pharma companies, has bought Spanish biosimilars development company Cinfa Biotech. The deal will

X

Mundipharma buys Spanish biosimilars firm Cinfa Biotech

https://pharmaphorum.com/news/mundipharma-buys-spanish-biosimilars-firm-cinfa-biotech/

Mundipharma to market Herceptin biosimilar in key EU markets

Mundipharma to market Herceptin biosimilar in key EU markets

Mundipharma’s third biosimilar tie-up with Celltrion

X

Mundipharma to market Herceptin biosimilar in key EU markets

https://pharmaphorum.com/news/mundipharma-market-celltrion-cancer-biosimilar-key-eu-markets/

Mundipharma buys rights to CellAct cancer drug

Mundipharma buys rights to CellAct cancer drug

Drug will be progressed through phase 3 trials in biliary tract cancer.

X

Mundipharma buys rights to CellAct cancer drug

https://pharmaphorum.com/news/mundipharma-cellact/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com